Page 2 - Jane Byram News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm on April 27 2021 10:00 PM SYDNEY--(BUSINESS WIRE)--#Veyonda--Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease. “Until enough people are vaccinated to achieve global herd immunity in the face of waves of emerging mutant strains of the virus, mill...

Noxopharm Files Septic Shock Treatment Patent for Veyonda® New indication doubles the commercial opportunity SYDNEY--(BUSINESS WIRE)--#Veyonda--Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental anti-cancer drug, Veyonda ® (idronoxil), in blocking the development of septic shock associated with infections such as COVID-19 and influenza viruses. Overall, septic shock is believed responsible for an estimated 10 million global deaths per year, with an estimated three million ad...